A multicenter, postmarketing surveillance of elobixibat in patients with chronic constipation in Japan: A final analysis report.

ABSTRACT:

Objective

An interim analysis of postmarketing surveillance reported the safety and efficacy of elobixibat, a laxative medication that inhibits the ileal bile acid transporter, at 4 weeks in approximately 1000 patients with chronic constipation in Japan. However, its long-term safety and efficacy in elderly patients remain unclear. This study aimed to conclude and report the final analysis of postmarketing surveillance, including 52-week safety and efficacy profiles in a clinical practice setting, using approximately 3000 patients.

Methods

The overall survey period spanned from June 2018 to May 2022. Observation periods were set at 4 weeks (4-week treatment period) and 52 weeks (52-week treatment period). Adverse drug reactions and efficacy outcomes, including defecation fre

SUBMITTER: Nakajima A 

PROVIDER: S-EPMC11863239 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature